Zap FlabFDA Update • February 2026
Compounded semaglutide is no longer legally available. Here’s what happened, why it matters, and what your options are now.
The Short Version
In October 2024, the FDA officially removed semaglutide from the drug shortage list. This single change has massive implications: compounding pharmacies can no longer legally produce semaglutide products.
Companies like Hims & Hers, who built significant businesses around compounded semaglutide, are now discontinuing these products. The FDA has been sending warning letters and taking enforcement action against providers who continue to offer compounded versions.
Why Compounding Was Allowed in the First Place
Under FDA rules, compounding pharmacies can produce copies of FDA-approved drugs only when those drugs are in shortage. When Ozempic and Wegovy demand exploded in 2022-2023, Novo Nordisk couldn’t keep up with production. The drugs landed on the FDA shortage list, which legally opened the door for compounding.
Compounded semaglutide became hugely popular because it was significantly cheaper — often $150-300/month compared to $1,000+ for brand-name versions without insurance at the time. Telehealth companies scaled rapidly to meet demand. (Note: as of 2026, brand-name self-pay prices have dropped to $349–$499/month, largely closing this price gap.)
What Changed
October 2024: The FDA removed semaglutide from the shortage list, stating that Novo Nordisk had resolved supply issues.
Late 2024 – Early 2026: The FDA began sending warning letters to compounding pharmacies and telehealth providers still offering compounded semaglutide.
February 2026: Major telehealth providers including Hims & Hers announced they would stop offering compounded semaglutide pills and injections.
What This Means for Patients
If you’ve been using compounded semaglutide, you’ll need to transition to other options:
Brand-Name Semaglutide (Ozempic/Wegovy)
The FDA-approved versions. Thanks to 2026 MFN pricing deals, self-pay costs have dropped dramatically to $349–$699/month (down from $900–$1,400). Novo Nordisk offers Ozempic/Wegovy at $499/month, with a $199/month intro offer for new patients. The new oral Wegovy pill starts at just $149/month. Medicare Part D now covers Wegovy and Zepbound for obesity (~$245/month).
Tirzepatide (Mounjaro/Zepbound)
Still on the FDA shortage list as of February 2026, meaning compounded tirzepatide remains legally available — for now. Many patients are switching to this option. Check our Ozempic vs Mounjaro comparison to understand the differences.
Insurance Coverage
Coverage has expanded significantly since 2023. If you were denied before, it may be worth trying again. Many plans cover GLP-1s for Type 2 diabetes, and some now cover them for weight loss.
Important Safety Note
Be cautious of providers still advertising “compounded semaglutide” — they may be operating in a legal gray area or worse. The FDA has flagged safety concerns with some compounded products, including incorrect dosing and contamination issues. If you’re considering any GLP-1 medication, work with a licensed healthcare provider who can prescribe FDA-approved options.
The Bottom Line
The era of compounded semaglutide is over — but the pricing landscape has shifted dramatically in patients’ favor. Thanks to the 2026 MFN deals, brand-name self-pay prices have dropped from $935–$1,349/month to $349–$499/month. The new oral Wegovy pill starts at $149/month, and Medicare now covers Wegovy and Zepbound for obesity. The argument for risking unregulated compounded products is weaker than ever.
If you’re currently on compounded semaglutide, don’t panic — but do start planning your next steps with your healthcare provider.
Need help understanding your options? Check our GLP-1 Guide for dosing schedules, medication comparisons, and cost calculators.